{"ok":true,"entity":{"id":"car-t-cell-therapy","name":"CAR T-cell Therapy","entityType":"concept","officialName":"CAR T-cell Therapy（キメラ抗原受容体T細胞療法）","canonicalName":"CAR T-cell Therapy","displayName":"CAR T-cell Therapy","category":"がん免疫細胞療法","shortDescription":"CAR T細胞療法は、患者自身のT細胞にキメラ抗原受容体（CAR）を発現させる遺伝子操作を加え、増やして体内に戻す免疫細胞療法。FDAが最初に承認したのは2017年（小児ALL向けのKymriah）で、NCIは血液がん向けの7製品を承認済みとして挙げる。固形がんへの応用は遅れており、自己免疫疾患への応用は検討段階にある。","primaryCluster":"biotech-genomics","parentEntity":null,"verificationStatus":"draft","website":"https://www.cancer.gov/about-cancer/treatment/research/car-t-cells","updatedAt":"2026-10-22T11:50:32.298Z","secondaryClusters":[],"alias":["キメラ抗原受容体T細胞療法","CAR T cell therapy"],"searchKeywords":["CAR-T","CAR T細胞療法","キメラ抗原受容体","CAR T-cell therapy","免疫細胞療法","血液がん","Kymriah","tisagenlecleucel"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-05-001","P-06-001"]}